Quarterly report pursuant to Section 13 or 15(d)

Schedule of Stock Options Issued and Outstanding Activities (Details)

v3.23.1
Schedule of Stock Options Issued and Outstanding Activities (Details) - 2018 Equity Plan [Member] - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Stock Options, Outstanding Stock Options Beginning 2,565,377  
Weighted Average Exercise Price, Weighted Average Grant Date Fair Value, Outstanding Stock Options Beginning $ 3.14  
Remaining Contractual Term (Years), Outstanding Stock Options Ending 8 years 10 months 24 days [1] 8 years 3 months 18 days
Outstanding Stock Options, Intrinsic Value Beginning [2] $ 428  
Number of Stock Options, Granted [3] 2,697,500  
Weighted Average Exercise Price, Granted [3] $ 1.31  
Number of Stock Options, Exercised  
Weighted Average Exercise Price, Exercised  
Number of Stock Options, Forfeited (210,419)  
Weighted Average Exercise Price, Forfeited $ 2.46  
Number of Stock Options, Outstanding Stock Options Ending 5,052,458 [1] 2,565,377
Weighted Average Exercise Price, Weighted Average Grant Date Fair Value, Outstanding Stock Options Ending $ 2.19 [1] $ 3.14
Outstanding Stock Options, Intrinsic Value Ending [2] $ 676 [1] $ 428
Number of Stock Options, Vested and exercisable stock options 1,254,494  
Weighted Average Exercise Price, Vested and exercisable stock options $ 2.67  
Remaining Contractual Term (Years), Vested and Exercisable 7 years  
Vested and Exercisable Stock Options, intrinsic value [2] $ 444  
[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2023 and December 31, 2022.
[2] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of March 31, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
[3] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.